

# Evaluation of pancreas composition and function during return to normal glucose tolerance in type 2 diabetes

**Submission date**

21/06/2011

**Recruitment status**

No longer recruiting

☐ Prospectively registered

☐ Protocol

**Registration date**

21/06/2011

**Overall study status**

Completed

☐ Statistical analysis plan

☒ Results

**Last Edited**

21/06/2016

**Condition category**

Nutritional, Metabolic, Endocrine

☐ Individual participant data

**Plain English summary of protocol**

Not provided at time of registration

## Contact information

**Type(s)**

Scientific

**Contact name**

Dr Sarah Steven

**Contact details**

Institute for Ageing and Health  
Campus for Ageing and Vitality  
Newcastle upon Tyne  
United Kingdom  
NE4 5PL

## Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

10274

# Study information

## Scientific Title

Evaluation of pancreas composition and function during return to normal glucose tolerance in type 2 diabetes

## Acronym

DRN 591

## Study objectives

The overall objective is to elucidate the pathophysiology of type 2 diabetes by defining the contribution of change in beta cell function and insulin sensitivity to the return to normal glucose homeostasis during definitive therapeutic intervention. The compelling in vitro and in vivo animal data for a direct adverse effect of fatty acid exposure on beta cell function and hepatic insulin sensitivity will be tested in vivo in people with type 2 diabetes by use of a newly devised magnetic resonance technique. The specific hypothesis will be tested that the early effect of bariatric surgery in normalising blood glucose in type 2 diabetes is brought about by the same mechanistic changes as seen during hypocaloric dieting.

## Ethics approval required

Old ethics approval format

## Ethics approval(s)

10/H0906/78

## Study design

Randomised interventional and observational treatment case-controlled study

## Primary study design

Interventional

## Secondary study design

Randomised controlled trial

## Study setting(s)

Hospital

## Study type(s)

Treatment

## Participant information sheet

Not available in web format, please use contact details to request a participant information sheet

## Health condition(s) or problem(s) studied

Topic: Diabetes Research Network, Metabolic and Endocrine; Subtopic: Type 2, Metabolic and Endocrine (all Subtopics); Disease: Metabolic

## Interventions

1. Subjects with and without type 2 diabetes will be investigated before and after gastric bypass surgery
2. Very low calorie diet (VLCD)
3. Subjects with T2DM will be randomised into 'surgery only' or 'VLCD+surgery' groups

**Intervention Type**

Mixed

**Primary outcome measure**

First phase insulin response at baseline, 1 week after intervention and 8 weeks after surgery

**Secondary outcome measures**

1. Liver fat and hepatic insulin sensitivity at baseline, 1 week after intervention and 8 weeks after surgery
2. The treatment induced changes in pancreatic fat content at baseline, 1 week after intervention and 8 weeks after surgery

**Overall study start date**

01/02/2011

**Completion date**

01/08/2012

**Eligibility****Key inclusion criteria**

1. Type 2 diabetes duration less than 15 years
2. On treatment with diet alone or diet plus oral agents
3. BMI 35-45m/kg<sup>2</sup>
4. Listed for gastric bypass surgery
5. HbA1c < 10%

**Participant type(s)**

Patient

**Age group**

Adult

**Sex**

Both

**Target number of participants**

Planned Sample Size: 28; UK Sample Size: 28

**Key exclusion criteria**

1. Waist circumference >150cm
2. Kidney dysfunction (serum creatinine >150 µmol/l)
3. Liver dysfunction (serum ALT > 2.5 times the upper limit of normal)
4. Contraindications to MRI (metal implants and claustrophobia)

5. Alcohol consumption >14 units per week
6. Treatment with thiazolidinediones, insulin, GLP1 analogues or steroids
7. History of bowel surgery or inflammatory bowel disease

**Date of first enrolment**

01/02/2011

**Date of final enrolment**

01/08/2012

## **Locations**

**Countries of recruitment**

England

United Kingdom

**Study participating centre**

**Institute for Ageing and Health**

Newcastle upon Tyne

United Kingdom

NE4 5PL

## **Sponsor information**

**Organisation**

Newcastle upon Tyne Hospitals NHS Foundation Trust

**Sponsor details**

Claremont Wing

Royal Victoria Infirmary

Queen Victoria Road

Newcastle Upon Tyne

England

United Kingdom

NE1 4LP

**Sponsor type**

Hospital/treatment centre

**Website**

<http://www.newcastle-hospitals.org.uk/>

**ROR**

<https://ror.org/05p40t847>

# Funder(s)

## Funder type

Research organisation

## Funder Name

European Foundation for the Study of Diabetes (Germany)

## Alternative Name(s)

The European Association for the Study of Diabetes, EFSD

## Funding Body Type

Private sector organisation

## Funding Body Subtype

Trusts, charities, foundations (both public and private)

## Location

Germany

# Results and Publications

## Publication and dissemination plan

Not provided at time of registration

## Intention to publish date

## Individual participant data (IPD) sharing plan

## IPD sharing plan summary

Not provided at time of registration

## Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	01/01/2016		Yes	No